Sox17 Promoter Methylation in Plasma DNA Is Associated With Poor Survival and Can Be Used as a Prognostic Factor in Breast Cancer

AbstractAberrant DNA methylation that leads to the inactivation of tumor suppressor genes is known to play an important role in the development and progression of breast cancer. Methylation status of cancer-related genes is considered to be a promising biomarker for the early diagnosis and prognosis of tumors. This study investigated the methylation status of the Sox17 gene in breast cancer tissue and its corresponding plasma DNA to evaluate the association of methylation levels with clinicopathological parameters and prognosis.The methylation status of the Sox17 gene promoter was evaluated with methylation-specific polymerase chain reaction (MSP) in 155 paired breast cancer tissue and plasma samples and in 60 paired normal breast tissue and plasma samples. Association of Sox17 methylation status with clinicopathological parameters was analyzed by &khgr;2 tests. Overall and disease-free survival (DFS) curves were calculated using Kaplan–Meier analysis, and the differences between curves were analyzed by log-rank tests.The frequency of Sox17 gene methylation was 72.9% (113/155) in breast cancer tissues and 58.1% (90/155) in plasma DNA. Sox17 gene methylation was not found in normal breast tissues or in their paired plasma DNA. There was a significant correlation of Sox17 methylation between corresponding tumor tissues and paired plasma DNA (r = 0.688, P < 0.001). Aberrant Sox17 methylation in cancer tissues and in plasma DNA was significantly associated with the tumor node metastasis stage (P = 0.035 and P = 0.001, respectively) and with lymph node metastasis (P < 0.001 and P = 0.001, respectively). Kaplan–Meier survival curves showed that aberrant Sox17 promoter methylation in cancer tissues and plasma DNA was associated with poor DFS (P < 0.005) and overall survival (OS) (P < 0.005). Multivariate analysis showed that Sox17 methylation in plasma DNA was an independent prognostic factor in breast cancer for both DFS (P = 0.020; hazard ratio [HR] = 2.142; 95% confidence interval [CI]: 1.128–4.067) and for OS (P = 0.001; HR = 4.737; 95% CI: 2.088–10.747).Sox17 gene promoter methylation may play an important role in breast cancer progression and could be used as a prognostic biomarker to identify patients at risk of developing metastasis or recurrence after mastectomy.

[1]  D. Hua,et al.  Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. , 2006, Cancer letters.

[2]  S. Morrison,et al.  Sox17 Dependence Distinguishes the Transcriptional Regulation of Fetal from Adult Hematopoietic Stem Cells , 2007, Cell.

[3]  J. Herman,et al.  SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma , 2010, Epigenetics.

[4]  Peter A. Jones,et al.  Rethinking how DNA methylation patterns are maintained , 2009, Nature Reviews Genetics.

[5]  J. Herman,et al.  Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. , 2008, Cancer research.

[6]  M. Villalobos,et al.  Quantitative detection of methylated ESR1 and 14-3-3-σ gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy , 2008, Cancer biology & therapy.

[7]  A. Zorn,et al.  Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. , 2004, Development.

[8]  E. Lianidou,et al.  SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. , 2013, Clinical chemistry.

[9]  S. Mirza,et al.  Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. , 2010, Life sciences.

[10]  S. Hanash,et al.  Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer , 2011, Nature Reviews Clinical Oncology.

[11]  V. Gallo,et al.  Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. , 2013, Cancer letters.

[12]  C. Sotiriou,et al.  Minimal residual disease and circulating tumor cells in breast cancer: open questions for research. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[13]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[14]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[15]  S. Morrison,et al.  Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. , 2013, The Journal of clinical investigation.

[16]  G. Schotta,et al.  Wnt/β-catenin signalling regulates Sox17 expression and is essential for organizer and endoderm formation in the mouse , 2013, Development.

[17]  M. Toyota,et al.  Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer , 2012, Tumor Biology.

[18]  Timothy J. Yeatman,et al.  Mapping Geographic Zones of Cancer Risk with Epigenetic Biomarkers in Normal Breast Tissue , 2006, Clinical Cancer Research.

[19]  E. van Marck,et al.  The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients , 2009, British Journal of Cancer.

[20]  V. Gallo,et al.  Identification of Sox17 as a Transcription Factor That Regulates Oligodendrocyte Development , 2006, The Journal of Neuroscience.

[21]  Z. Barekati,et al.  Cell-free DNA in the circulation as a potential cancer biomarker. , 2011, Anticancer research.

[22]  Menghong Sun,et al.  Sox17 regulates proliferation and cell cycle during gastric cancer progression. , 2011, Cancer letters.

[23]  J. Herman,et al.  SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. , 2012, Discovery medicine.

[24]  M. Taketo,et al.  Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. , 2009, Gastroenterology.

[25]  R. Schwartz,et al.  Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells , 2007, Proceedings of the National Academy of Sciences.

[26]  H. Mulcahy,et al.  Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients , 2004, Cancer and Metastasis Reviews.

[27]  A. Zorn,et al.  Sox17 and β-catenin cooperate to regulate the transcription of endodermal genes , 2004 .

[28]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[29]  E. Chatzaki,et al.  Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival , 2013, Clinical chemistry and laboratory medicine.

[30]  Li-hua Hu,et al.  Multigene Methylation in Serum of Sporadic Chinese Female Breast Cancer Patients as a Prognostic Biomarker , 2008, Oncology.

[31]  P. Vouros,et al.  Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids. , 2011, International journal of mass spectrometry.

[32]  Aaron M. Zorn,et al.  Sox17 and Sox4 Differentially Regulate β-Catenin/T-Cell Factor Activity and Proliferation of Colon Carcinoma Cells , 2007, Molecular and Cellular Biology.

[33]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[34]  Z. Shao,et al.  Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer , 2010, Breast Cancer Research and Treatment.

[35]  R. Murphy,et al.  DNA methylation in breast and colorectal cancers , 2007, Modern Pathology.

[36]  V. Levenson,et al.  Methylation patterns in cell‐free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients , 2011, International journal of cancer.

[37]  P. Lara,et al.  Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis , 2010, BMC Cancer.

[38]  Jose M. Silva,et al.  Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations , 2001, Genes, chromosomes & cancer.

[39]  H. Bojar,et al.  Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease , 2010, European journal of medical research.

[40]  P. Lu,et al.  Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression , 2014, International journal of cancer.

[41]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[42]  C. Marth,et al.  Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients , 2011, Breast Cancer Research and Treatment.

[43]  V. Gallo,et al.  SRY-Box Containing Gene 17 Regulates the Wnt/β-Catenin Signaling Pathway in Oligodendrocyte Progenitor Cells , 2011, The Journal of Neuroscience.

[44]  A. Bardelli,et al.  Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. , 2014, Cancer treatment reviews.

[45]  Mariano Provencio,et al.  Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Jingde Zhu,et al.  Use of DNA methylation for cancer detection: promises and challenges. , 2009, The international journal of biochemistry & cell biology.

[47]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[48]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.